Protalix BioTherapeutics (PLX) Announces Commencement of PRX-105 Phase I
Tweet Send to a Friend
Protalix BioTherapeutics, Inc. (AMEX: PLX) announced today that it has initiated a phase I clinical trial of PRX-105, the Company's ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
